nference is proud to support Blueprint Medicines in their mission to better understand the real-world burden and natural history of #ISM. Leveraging our #AI platform, researchers from Blueprint Medicines, Mayo Clinic and nference were able to analyze de-identified electronic health record data. The study revealed significant differences in healthcare utilization and #allergy prevalence for patients with ISM compared to matched controls. The findings that were presented today at #AAAAI25 reflect the importance of longitudinal real-world data in understanding the disease burden on ISM patients. Learn more about the AI platform powering breakthrough clinical research: https://lnkd.in/eqWTyzTd #Mastocytosis #RWE #PrecisionMedicine #AIinHealthcare #EHR
In our efforts to truly understand the experiences of people living with indolent systemic #mastocytosis (ISM), we work with partners to collect and analyze real-world data that inform our ability to improve and extend patients’ lives. At #AAAAI25 today, we're presenting findings from a study in partnership Dr. Thanai Pongdee to evaluate the real-world disease burden and natural history of ISM. This study involves the analysis of de-identified electronic health record data from the Mayo Clinic Platform via the nference Analytics Platform. Learn more below: